Long-Term, Real-World Effectiveness of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis: Data from >= 6 Years in the Tysabri (R) Observational Program (Top) Portuguese, Spanish, and Global Cohorts
AuthID
P-00P-0Q3
P-00P-0Q3